These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27020585)

  • 1. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
    Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
    Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
    Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
    Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis.
    Jin C; Huang Y; Nasim M; Yang Y; Lee L
    Int J Surg Pathol; 2019 Oct; 27(7):706-712. PubMed ID: 31146625
    [No Abstract]   [Full Text] [Related]  

  • 7. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
    Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
    Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
    Puripat N; Loharamtaweethong K
    Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.
    Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC
    Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
    Tracht J; Zhang K; Peker D
    J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.
    Veras E; Malpica A; Deavers MT; Silva EG
    Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
    Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
    Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma.
    Duregon E; Molinaro L; Volante M; Ventura L; Righi L; Bolla S; Terzolo M; Sapino A; Papotti MG
    Mod Pathol; 2014 Sep; 27(9):1246-54. PubMed ID: 24434900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
    Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
    Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
    Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
    Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 index and mitotic count: Correlation and variables affecting the accuracy of the quantification in endocrine/neuroendocrine tumors.
    Huang W; Nebiolo C; Esbona K; Hu R; Lloyd R
    Ann Diagn Pathol; 2020 Oct; 48():151586. PubMed ID: 32836178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
    Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
    Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.